Stay updated on Galinpepimut-S and Pembrolizumab Combo in Advanced Cancers Clinical Trial
Sign up to get notified when there's something new on the Galinpepimut-S and Pembrolizumab Combo in Advanced Cancers Clinical Trial page.

Latest updates to the Galinpepimut-S and Pembrolizumab Combo in Advanced Cancers Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.2; study content, eligibility, outcomes, and locations remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check26 days agoChange DetectedRemoved the generic government funding notice from the page; the study details, locations, and eligibility criteria remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check47 days agoChange DetectedResults for NCT03761914 have been posted, including ORR, PFS, and OS, along with updated enrollment figures and completion dates.SummaryDifference0.3%

- Check69 days agoChange Detected- Updated version to v3.2.0 and added an important operating-status notice about funding and center operations. - Removed specific Genetic and Rare Diseases Information Center resources on Acute myeloid leukemia and Small cell lung carcinoma (v3.1.0 resources).SummaryDifference2%

- Check76 days agoChange DetectedThe page now indicates a new version (v3.1.0) and removes the topic reference 'Ovarian cancer', signaling a shift in core content and subject focus.SummaryDifference0.1%

- Check90 days agoChange DetectedMinor update: version bump v3.0.1 -> v3.0.2 with removal of 'Back to Top'. Core content remains unchanged.SummaryDifference0.1%

Stay in the know with updates to Galinpepimut-S and Pembrolizumab Combo in Advanced Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Galinpepimut-S and Pembrolizumab Combo in Advanced Cancers Clinical Trial page.